Genome-wide association analysis of age-at-onset in Alzheimer's disease

The risk of Alzheimer's disease (AD) is strongly determined by genetic factors and recent genome-wide association studies (GWAS) have identified several genes for the disease risk. In addition to the disease risk, age-at-onset (AAO) of AD has also strong genetic component with an estimated heritability of 42%. Identification of AAO genes may help to understand the biological mechanisms that regulate the onset of the disease. Here we report the first GWAS focused on identifying genes for the AAO of AD. We performed a genome-wide meta-analysis on three samples comprising a total of 2222 AD cases. A total of ∼2.5 million directly genotyped or imputed single-nucleotide polymorphisms (SNPs) were analyzed in relation to AAO of AD. As expected, the most significant associations were observed in the apolipoprotein E (APOE) region on chromosome 19 where several SNPs surpassed the conservative genome-wide significant threshold (P<5E-08). The most significant SNP outside the APOE region was located in the DCHS2 gene on chromosome 4q31.3 (rs1466662; P=4.95E-07). There were 19 additional significant SNPs in this region at P<1E-04 and the DCHS2 gene is expressed in the cerebral cortex and thus is a potential candidate for affecting AAO in AD. These findings need to be confirmed in additional well-powered samples.

[1]  E M Wijsman,et al.  The number of trait loci in late-onset Alzheimer disease. , 2000, American journal of human genetics.

[2]  Michael Weiner,et al.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.

[3]  C. Di Menza,et al.  VLDL receptor polymorphism, cognitive impairment, and dementia , 2001, Neurology.

[4]  Suzette J. Bielinski,et al.  NRXN3 Is a Novel Locus for Waist Circumference: A Genome-Wide Association Study from the CHARGE Consortium , 2009, PLoS genetics.

[5]  Sarah E. Brockwell,et al.  A comparison of statistical methods for meta‐analysis , 2001, Statistics in medicine.

[6]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[7]  Rajesh Pahwa,et al.  Age at onset in two common neurodegenerative diseases is genetically controlled. , 2002, American journal of human genetics.

[8]  R. Maki,et al.  ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family. , 2000, Genomics.

[9]  L. Chan,et al.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins , 2009, Brain Research.

[10]  M. Borodovsky,et al.  Identification of new human cadherin genes using a combination of protein motif search and gene finding methods. , 2004, Journal of molecular biology.

[11]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[12]  D. Drachman,et al.  Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease : what physicians know, and what they should know , 1995 .

[13]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[14]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[15]  V. Pankratz,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Nature Genetics.

[16]  O. Lopez,et al.  Replication study of genome‐wide associated SNPs with late‐onset Alzheimer's disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[17]  R. Rosenthal,et al.  Genomewide suggestive linkage of opioid dependence to chromosome 14q. , 2007, Human molecular genetics.

[18]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[19]  D. Drachman,et al.  Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. , 1995, Archives of neurology.

[20]  M. McCarthy,et al.  Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes , 2008, Nature Genetics.

[21]  Vladimir I. Vladimirov,et al.  Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics , 2009, Molecular Psychiatry.

[22]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[23]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[24]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[25]  S. DeKosky,et al.  Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease , 2006, Neurobiology of Aging.

[26]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[27]  R. Hamman,et al.  The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. , 1995, Atherosclerosis.

[28]  P. Bosco,et al.  The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. , 2010, Journal of Alzheimer's disease : JAD.

[29]  E. Stanley,et al.  Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis , 2007, Journal of Cell Science.

[30]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[31]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[32]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[33]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[34]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[35]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.